Vera Ghali: 2026 ASH–ISTH Recommendations on Pediatric VTE Prevention
Vera Ghali, Member of the Lebanese Order of Physicians and Lebanese Pediatric Society, shared Blood Journals Portfolio‘s post on X:
“The 2026 ASH-ISTH guidelines and recommendations on anti-coagulant prophylaxis for pediatric patients at risk of Venous Thromboembolism (VTE).
The panel underscores the necessity to individualize anti-coagulant prophylaxis for pVTE and resorting to careful assessment of each child’s thrombotic and bleeding risks, with special attention to children’s specificities across different subgroups.
The panel highlights that children with leukemia and lymphoblastic lymphoma (LBL) who benefit the most from anticoagulation are those who are older than 10 years, those with obesity, T-cell immunophenotype, high-risk Acute Lymphoblastic Leukemia (ALL), and children with a personal or family history of thrombosis.
Factors that increase bleeding with anticoagulant prophylaxis are: younger age, severe thrombocytopenia, renal dysfunction, and previous bleeding.
Furthermore, asparaginase is a severe pro-thrombotic agent, consequently, anticoagulation should be initiated during asparaginase-containing chemotherapy cycles and discontinued as soon as the asparaginase hypercoagulable effects wear off.”
Blood Journals Portfolio shared a post on X about a recent article by Marisol Betensky et al., published in Blood:
“New in Blood Advances: ASH/ISTH 2026 guidelines for anticoagulant prophylaxis in pediatric patients at risk of venous thromboembolism.”
Title: ASH/ISTH 2026 guidelines for anticoagulant prophylaxis in pediatric patients at risk of venous thromboembolism
Authors: Marisol Betensky, Muayad Azzam, Rachel Bercovitz, Rukhmi V Bhat, Tina Biss, Brian Branchford, Leonardo R Brandão, Anthony K C Chan, E Vincent S Faustino, Qais Hamarsha, Julie Jaffray, Sophie Jones, Hassan Kawtharany, Bryce A Kerlin, Jana Khawandi, Grace Krider, Nicole Kucine, Riten Kumar, Christoph Male, Paul Monagle, Marie-Claude Pelland-Marcotte, Leslie Raffini, Chittalsinh Raulji, Sarah E Sartain, Clifford M Takemoto, Cristina Tarango, C Heleen van Ommen, Maria C Velez, Sara K Vesely, John Wiernikowski, Suzan Williams, Hope P Wilson, Gary Woods, Reem A Mustafa
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 11, 2026, 15:42Tareq Abadl: The Clinical Impact of Kell Alloimmunization
-
Nov 11, 2026, 15:30Alejandro González Veliz: Does PCI Change The Long-Term Outcome In Stable Coronary Artery Disease?
-
Nov 11, 2026, 15:25Preparing for the SoHO Regulation – EBA Board Convenes in Vienna – European Blood Alliance
-
Nov 11, 2026, 15:20Vaidehi Prasanth: IV Iron in Heart Failure – Exploring Hospitalisation Benefits vs. Infection Risk in Open Heart
-
Nov 11, 2026, 15:18Stefan Prendić: Can Algorithms Support Antibody Identification in Immunohematology?
-
Nov 11, 2026, 15:12Perioperative Challenges in Hemophilia Patients on Rebalancing Therapies
-
Nov 11, 2026, 15:03Maria Elisa Mancuso: World-Renowned Faculty and 33 Global Participants Unite at Hemophilia Academy 2026
-
Nov 11, 2026, 15:01Hassan Raza: The JAK2 V617F Revolution
-
Nov 11, 2026, 14:57Edward Lee Carter: Factor Xla Inhibition Enters Clinical Practice – FDA Approval of Asundexian